The world's first and only MPS I enzyme replacement therapy, approved in China with a Lassaloniase thick solution

Introduction: Recently, the State Drug Administration approved Genzyme's injection with Laronine enrichment solution (commodity name Aizan/Aldurazyme) for the sale of long-term enzyme replacement therapy for patients with mucosal polysaccharide type I for the treatment of non-nervous system manifestations of the disease through a priority review and approval processon June 3,, the State Drug Administration announced that the State Drug Administration approved Genzyme's injection of Laroninase Thick Solution (commodity name Aizan/Aldurazyme) for the sale of long-term enzyme replacement therapy for patients with mucosal polysaccharide type I for the treatment of non-nervous system manifestations of the disease through a priority review and approval processmuscosal polysaccharide myditas Type I (MPSI) is a rare disease of autosomal recessive genetics caused by a lack of alpha-L-adu glyconuclease, which can lead to excessive accumulation of glycosamine polysaccharides in all organs and tissues of the body, which can lead to life-threatening accumulationAs an enzyme replacement therapy for such patients, this approved drug has been included in the second batch of clinically urgently needed overseas listed drugsAnd it is worth mentioning that the injection of the world's first and only MPSI enzyme replacement therapy with the Laroni enzyme concentrator solution, first developed by BioMarin for the treatment of patients with mucosal polysaccharide mysiosis type I, the company is working on the development of rare disease drugs2003, Laronidase was approved by the FDA to be listed in the U.S., becoming the world's first therapeutic drug for the rare genetic disease muscosal polysaccharide mydite type I, and is suitable for patients with curr and Hurler-Scheie-type muscosal polysaccharide I (MPSI) as well as patients with moderate to severe symptoms of Scheie, including Hurley syndrome, muscosalized lipid i type I, and other nutritional disordersBioMarin was acquired by Sanofi, the latter acquired the former's rare disease drug pipelineTo date, LaRonien has been licensed to market in several countries around the world, including Europe and JapanMarch 2019, the Drug Review Center of the State Drug Administration issued the second batch of "Clinically Urgent overseas New Drugs List", which published a list of 30 overseas listed clinically urgently needed new drugs, mainly rare disease drugs, including Sanofi's injected laronine concentrated solutionJune 2019, Sanofi submitted an application for the listing of a lethal solution for injections with Laroninase, a year after it was officially approved for listing in China, giving hope to Chinese patientsSince the publication of the list of drugs listed overseas in clinical urgent need, the State Drug Administration has approved more than 30 varieties of import registrationNext, the State Drug Administration will continue to implement the relevant requirements for deepening the reform of the drug review and approval system, and continuously speed up the listing of clinically urgentdrugs in China to better meet the people's demand for drug use